|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Friends Research Institute, Inc. |
|---|---|
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000245 |
Purpose
The purpose of this study is to confirm whether a blood level ""ceiling"" exists on desipramine effect in cocaine abuse.
| Condition | Intervention | Phase |
|---|---|---|
|
Cocaine-Related Disorders Substance-Related Disorders |
Drug: Desipramine |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Evaluation of a Desipramine Ceiling in Cocaine Abuse |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, California | |
| Friends Research Institute | |
| Los Angeles, California, United States, 90025 | |
| Principal Investigator: | Frank Gawin, M.D. | Friends Research Institute, Inc. |
More Information
| Study ID Numbers: | NIDA-08082-1, R01-08082-1 |
| Study First Received: | September 20, 1999 |
| Last Updated: | August 16, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000245 History of Changes |
| Health Authority: | United States: Federal Government |
|
Cocaine-Related Disorders Neurotransmitter Agents Adrenergic Agents Mental Disorders Psychotropic Drugs Substance-Related Disorders |
Disorders of Environmental Origin Desipramine Cocaine Antidepressive Agents Antidepressive Agents, Tricyclic |
|
Cocaine-Related Disorders Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Disorders of Environmental Origin |
Enzyme Inhibitors Desipramine Pharmacologic Actions Antidepressive Agents, Tricyclic Pathologic Processes Mental Disorders Therapeutic Uses Substance-Related Disorders Central Nervous System Agents Antidepressive Agents |